Congress Asset Management’s Pacira BioSciences PCRX Stock Holding History

Congress Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-87,941	Closed	-$2.52M	–	373
2024 Q2	$2.52M	Sell	87,941 -1,021	-1%	-$29.1K	0.02%	264
2024 Q1	$2.6M	Buy	88,962 +1,095	+1%	+$33.6K	0.02%	265
2023 Q4	$2.96M	Buy	87,867 +315	+0.4%	+$9.22K	0.02%	272
2023 Q3	$2.69M	Buy	87,552 +117	+0.1%	+$4.22K	0.02%	264
2023 Q2	$3.5M	Buy	87,435 +1,097	+1%	+$45.4K	0.03%	248
2023 Q1	$3.52M	Buy	86,338 +8,564	+11%	+$341K	0.03%	241
2022 Q4	$3M	Buy	77,774 +574	+0.7%	+$27.9K	0.03%	250
2022 Q3	$4.11M	Buy	77,200 +35,474	+85%	+$1.97M	0.04%	217
2022 Q2	$2.43M	Buy	+41,726	New	+$2.73M	0.02%	262

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Congress Asset Management's PCRX Position: Q3 2024 in Review

Congress Asset Management sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 87,941 shares — an estimated $2.52M sold.

Congress Asset Management first reported a position in PCRX in Q2 2022 and held it in 9 quarters. The position peaked at $4.11M in Q3 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

Congress Asset Management reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
Congress Asset Management sold 87,941 Pacira BioSciences shares in Q3 2024, an estimated $2.52M.
Congress Asset Management first reported a position in Pacira BioSciences in Q2 2022 and held it in 9 quarters.
Congress Asset Management's Pacira BioSciences position peaked at $4.11M in Q3 2022.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Congress Asset Management's 13F filing for Q3 2024, filed 28 Oct 2024.